91 related articles for article (PubMed ID: 23597178)
1. Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience.
Elkjær MC; Borre M
Scand J Urol; 2014 Feb; 48(1):27-33. PubMed ID: 23597178
[TBL] [Abstract][Full Text] [Related]
2. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
3. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
Dhar N; Ward JF; Cher ML; Jones JS
BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
[TBL] [Abstract][Full Text] [Related]
4. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
7. Only carefully selected patients may have a beneficial effect of salvage cryoablation in recurrent prostate cancer after radiotherapy.
Elkjær MC; Borre M
Dan Med J; 2013 Dec; 60(12):A4756. PubMed ID: 24355453
[TBL] [Abstract][Full Text] [Related]
8. Five-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (EERPE) for prostate cancer: results from a medium-volume UK centre.
McNeill SA; Good DW; Stewart GD; Stolzenburg JU
BJU Int; 2014 Mar; 113(3):449-57. PubMed ID: 23980640
[TBL] [Abstract][Full Text] [Related]
9. Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.
Bossier R; Sanguedolce F; Territo A; Vanacore D; Martínez C; Regis F; Gallioli A; Mercade A; Mosquera L; Aumatell J; Balana J; Carlderon J; Huguet J; Gaya JM; Palou J; Breda A
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):172-178. PubMed ID: 32033834
[TBL] [Abstract][Full Text] [Related]
10. Robot assisted radical prostatectomy for elderly patients with high risk prostate cancer.
Rogers CG; Sammon JD; Sukumar S; Diaz M; Peabody J; Menon M
Urol Oncol; 2013 Feb; 31(2):193-7. PubMed ID: 21803614
[TBL] [Abstract][Full Text] [Related]
11. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
12. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?
Punnen S; Meng MV; Cooperberg MR; Greene KL; Cowan JE; Carroll PR
BJU Int; 2013 Aug; 112(4):E314-20. PubMed ID: 23451984
[TBL] [Abstract][Full Text] [Related]
13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
14. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
15. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
[TBL] [Abstract][Full Text] [Related]
16. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.
Busch J; Stephan C; Herold A; Erber B; Kempkensteffen C; Hinz S; Lein M; Weikert S; Miller K; Magheli A
BJU Int; 2012 Dec; 110(11 Pt C):E985-90. PubMed ID: 22672442
[TBL] [Abstract][Full Text] [Related]
17. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
Siddiqui SA; Mynderse LA; Zincke H; Hoffmann NE; Lobo JR; Wilson TM; Kawashima A; Davis BJ; Blute ML
Urology; 2007 Jul; 70(1):80-5. PubMed ID: 17656213
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
19. Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy.
Kunz I; Musch M; Roggenbuck U; Klevecka V; Kroepfl D
BJU Int; 2013 Mar; 111(3 Pt B):E24-9. PubMed ID: 22947135
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
